Table 1.
Clinical characteristics of patients with Multiple Myeloma and auto-HCT with and without CKS1B gene amplification.
| Group statistics
|
P-value
|
||
|---|---|---|---|
| Patients without CKS1B gene amplfification (n=58) | Patients with CKS1B gene amplfification (n=58) | ||
|
|
|
||
| Median age at TP (range) | 61 (33–75) | 60 (34–78) | 0.737 |
| Sex (F/M) | 29/29 | 26/32 | 0.577 |
| Hb, g/dl, median (range)* | 10.0 (5.4–16.3) | 9.9 (5.5–16.7) | 0.688 |
| Calcium, mg/dl, median (range)* | 9.6 (8.3–16.1) | 9.5 (8.0–14.2) | 0.812 |
| Creatinine, mg/dl, median (range)* | 1.0 (0.6–10.6) | 1.0 (0.5–11.8) | 0.911 |
| LDH, U/l, median (range)*, (n=34 and 44) | 428 (3–953) | 433 (115–2720) | 0.467 |
| % Bone marrow plasma cells, (range)* | 50 (1–100) | 60 (5–96) | 0.295 |
| ISS Stage III, n (%) (n= 42 and 50) | 15 (37) | 18 (36) | 0.954 |
| Induction therapy bortezomib-based | 53 (91) | 39 (70) | 0.004 |
| Time from diagnosis to auto-HCT, years, median (range) | 0.86 (0.30–12.35) | 0.61 (0.3–11.77) | 0.142 |
| Disease status at auto-HCT, n (%) | |||
| First remission | 33 (57) | 33 (57) | 1.000 |
| Relapse | 25 (43) | 25 (43) | |
| CR/VGPR/PR before auto-HCT, n (%) | 47 (81) | 46 (79) | 0.887 |
| CR, n (%) | 4 (7) | 10 (17) | |
| VGPR, n (%) | 14 (24) | 10 (17) | |
| PR, n (%) | 28 (48) | 27 (47) | |
| Prep regimen: Melphalan alone, n (%) | 43 (74) | 45 (78) | 0.664 |
*
at diagnosis, Hb indicates Hemoglobin, CR indicates complete response; NR, no response; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response; TP, Transplantation; auto-HCT, autologous hematopoietic stem cell transplantation; ISS, International Staging-System.